CLINICAL TRIALS PROFILE FOR PLECANATIDE
✉ Email this page to a colleague
All Clinical Trials for plecanatide
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01429987 ↗ | The Plecanatide Chronic Idiopathic Constipation (CIC) Study | Completed | Parexel | Phase 2/Phase 3 | 2011-10-01 | This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC). |
NCT01429987 ↗ | The Plecanatide Chronic Idiopathic Constipation (CIC) Study | Completed | Bausch Health Americas, Inc. | Phase 2/Phase 3 | 2011-10-01 | This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC). |
NCT01429987 ↗ | The Plecanatide Chronic Idiopathic Constipation (CIC) Study | Completed | Synergy Pharmaceuticals Inc. | Phase 2/Phase 3 | 2011-10-01 | This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC). |
NCT01722318 ↗ | The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) | Completed | Bausch Health Americas, Inc. | Phase 2 | 2012-11-01 | This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C. |
NCT01722318 ↗ | The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) | Completed | Synergy Pharmaceuticals Inc. | Phase 2 | 2012-11-01 | This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C. |
NCT01919697 ↗ | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) | Completed | INC Research | Phase 3 | 2013-08-01 | This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC). |
NCT01919697 ↗ | Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) | Completed | Syneos Health | Phase 3 | 2013-08-01 | This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for plecanatide
Condition Name
Condition Name for plecanatide | |
Intervention | Trials |
Chronic Idiopathic Constipation | 5 |
Irritable Bowel Syndrome Characterized by Constipation | 3 |
Irritable Bowel Syndrome With Constipation | 2 |
Abdominal Pain | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for plecanatide
Trials by Country
Clinical Trial Progress for plecanatide
Clinical Trial Phase
Clinical Trial Sponsors for plecanatide
Sponsor Name